GSK, Spero’s oral antibiotic wins first FDA nod for complicated UTI

FDA Approves GSK and Spero's Oral Carbapenem Utebzi for cUTI

GSK and Spero Therapeutics have received FDA approval for Utebzi (tebipenem pivoxil) for complicated urinary tract infections (cUTIs) caused by susceptible pathogens in patients with limited or no alternative treatment options. This marks the first oral carbapenem antibiotic available in the U.S. for cUTIs, addressing a significant unmet need where over 3 million cases annually often face drug-resistant pathogens. The approval follows a previous rejection in June 2022 and a subsequent $66 million upfront licensing deal from GSK to Spero in December 2022, leading to a successful refiling in December 2025. The Phase 3 PIVOT-PO study demonstrated Utebzi's non-inferiority to intravenous imipenem-cilastatin.

• First Oral Carbapenem for cUTI: Utebzi (tebipenem pivoxil) is the first oral carbapenem antibiotic to receive FDA approval for complicated urinary tract infections (cUTIs) in the U.S. This offers a crucial new treatment option for adult patients with susceptible pathogens who have limited or no alternative therapies, particularly given the rising challenge of drug-resistant infections that often require intravenous carbapenems.
• Regulatory Journey and Partnership: The drug's path to approval involved an initial FDA rejection in June 2022 due to insufficient Phase 3 data. Subsequently, GSK acquired an exclusive worldwide license from Spero Therapeutics in December 2022 for $66 million upfront and up to $750 million in milestones, leading to a successful refiling in December 2025 after new data from the PIVOT-PO study.
• Efficacy Demonstrated in PIVOT-PO Study: The FDA approval was supported by data from the Phase 3 PIVOT-PO study, which showed Utebzi was non-inferior to intravenous imipenem-cilastatin. The study reported an overall treatment success rate of 58.5% for Utebzi, compared to 60.2% for the intravenous comparator, leading to an independent data board recommending early stoppage for efficacy in May 2025.

Addressing the Unmet Needs in Complicated UTIs

Complicated urinary tract infections (cUTIs) present a compounding set of clinical and microbiological challenges that continue to strain standard therapeutic frameworks. The global rise of antimicrobial resistance — particularly among Gram-negative uropathogens — has significantly narrowed empiric and definitive treatment options, while structural and host-related factors further complicate management.

• Escalating antimicrobial resistance across key uropathogens: Resistance among traditional uropathogens, including E. coli and Klebsiella pneumoniae, has reached clinically significant levels. Resistance rates are highest for ciprofloxacin (35.4%) and trimethoprim/sulfamethoxazole (31.7%), with high resistance also documented against amoxicillin-clavulanic acid (>88%) and third-generation cephalosporins (51–75%). Carbapenems and amikacin retain comparatively lower resistance rates (<20%), though carbapenem-resistant strains of E. coli, Klebsiella, and Enterobacter spp. have been identified, posing a significant public health threat.

• ESBL-producing organisms as a dominant driver of multidrug resistance: Among Gram-negative isolates, 17.3% were ESBL-positive in a 2019–2024 study. ESBL production was identified as the strongest independent predictor of resistance to multiple antimicrobial classes, including ciprofloxacin (aOR 9.83), amoxicillin/clavulanic acid (aOR 3.22), trimethoprim/sulfamethoxazole (aOR 2.89), and cefotaxime (aOR 1,337). The global dissemination of CTX-M-15 ESBL-producing E. coli ST-131 has particularly compromised empiric treatment strategies.

• Emergence of extensively resistant and pan-drug resistant organisms: Multidrug resistance (MDR) has been observed in 25.05% of uropathogenic isolates, with pan-drug resistance (PDR) documented in 10.77%. NDM-1-producing E. coli and K. pneumoniae, along with resistant Acinetobacter species, are being isolated with increasing frequency. K. pneumoniae demonstrates a more extensive resistance profile than E. coli, and MDR/PDR burden is disproportionately high among patients aged 60 years and above.

• Limitations of empiric therapy and risk of treatment failure: Therapy against uropathogens is predominantly administered empirically, which may lead to unsuccessful outcomes, recurrence, and further selection of resistant variants. The absence of effective oral antibiotic options in the context of rising resistance is increasingly necessitating parenteral treatment strategies, raising care complexity and costs.

• Inadequate development pipeline and gaps in novel agent coverage: Several antimicrobials in development lack full-spectrum activity against key Gram-negative organisms, particularly MDR Pseudomonas aeruginosa. Serious therapeutic gaps persist for fluoroquinolone-resistant E. coli, MDR P. aeruginosa, and methicillin-resistant S. aureus (MRSA), the latter showing an increasing frequency among catheter-associated UTIs.

• Biofilm formation, catheter-associated infection, and microbiome disruption: Uropathogenic E. coli (UPEC) strains utilize multiple virulence factors for adhesion, invasion, and biofilm formation, rendering infections refractory to standard antibiotic courses. Technologic progress in developing adherence-resistant catheter materials remains disappointing. Furthermore, prolonged antibiotic use disrupts intestinal microbiota and facilitates the selection of drug-resistant uropathogenic variants, underscoring the need for non-antimicrobial therapeutic alternatives.

PIVOT-PO: The Pivotal Data Behind Utebzi's Approval

The pivotal clinical trials for complicated urinary tract infections (cUTI) span a range of designs, from early cephalosporin comparisons to modern phase 3 noninferiority trials incorporating composite microbiological and clinical endpoints. Across the most recent studies, randomized double-blind active-controlled designs with stringent pathogen inclusion criteria and test-of-cure assessments have become the methodological standard. The table below consolidates key design parameters and endpoints across landmark cUTI trials.

Utebzi's Role in the Evolving cUTI Treatment Landscape

Current standard-of-care guidelines for cUTIs emphasize pathogen-directed therapy, though empiric broad-spectrum antibiotic coverage remains a cornerstone of initial management—particularly in high-risk patients prone to urosepsis or an unfavorable clinical course. Recommended empiric agents include carbapenems, piperacillin-tazobactam, amikacin, and tigecycline. The choice of antibiotic is further nuanced by the spectrum of cUTI syndromes—acute uncomplicated cystitis, pyelonephritis, prostatitis, and catheter-associated UTIs each carry distinct therapeutic considerations—as well as patient-level factors such as degree of immunosuppression and genitourinary anatomy. Patients with urological obstruction or kidney transplants may require specialized, multidisciplinary management. This complexity is compounded by resistance trends: overall resistance rates of 74.5% for penicillin, 58.82% for trimethoprim-sulfamethoxazole, and 49% for fluoroquinolones have been documented, with 40.2% of patients presenting with multidrug-resistant (MDR) infections—underscoring the limitations of traditional empiric regimens.

Regarding treatment duration, a 2023 analysis of 1,099 hospitalized cUTI patients with associated bacteremia demonstrated that 10 days of therapy was non-inferior to 14 days (aOR: 0.99; 95% CI: 0.52–1.87), while 7-day courses were associated with significantly increased odds of recurrence compared to 14-day courses (aOR: 2.54; 95% CI: 1.40–4.60). Notably, when the 7-day versus 14-day analysis was restricted to the 627 patients who either remained on intravenous beta-lactam therapy or transitioned to highly bioavailable oral agents, this difference in recurrence outcomes was no longer observed (aOR: 0.76; 95% CI: 0.38–1.52). These findings suggest that 7 days of therapy may be sufficient when antibiotic bioavailability is optimized, while 10 days remains the appropriate target for patients not receiving agents with comparable intravenous and oral bioavailability. From an efficacy standpoint, 2024 data indicate that meropenem-vaborbactam leads combination regimens with a 98.4% cure rate, followed by piperacillin-tazobactam at 94% and ceftazidime-avibactam at 87.5%; among monotherapies, meropenem achieved the highest cure rate at 91.4%.

Despite these advances, significant gaps in the cUTI guideline landscape persist. Current national and international guidelines do not uniformly address the full range of patient cohorts, including variations by age, sex, or comorbidity burden, and the importance of stratified cumulative antibiograms at the individual healthcare facility level has been increasingly recognized. Prospective, well-designed studies focusing on uniform UTI definitions, pathogen characteristics, and optimized antibiotic selection and duration are still needed. Additionally, no consistent reductions in cUTI rates have been identified from studies examining perioperative antibiotic regimens following radical cystectomy, and guideline adherence remains suboptimal in part due to heterogeneity in study design. Appropriate drug selection and treatment adherence are considered critical to preventing cUTIs and curbing the further emergence of antibiotic resistance.

Oral Carbapenem: A New Frontier in cUTI Management

The landscape of treating complicated urinary tract infections (cUTIs) is undergoing a significant evolution, driven by the persistent challenge of antimicrobial resistance. The recent FDA approval of Utebzi, the first oral carbapenem, represents a pivotal moment in this fight. For years, carbapenems have been the go-to agents for serious infections caused by multidrug-resistant (MDR) pathogens, particularly extended-spectrum β-lactamase (ESBL)-producing Enterobacterales, which are increasingly prevalent in both community- and hospital-acquired UTIs. However, their administration has largely been confined to intravenous (IV) settings, often necessitating hospitalization.

Utebzi's introduction offers a compelling alternative, potentially transforming patient management by enabling a seamless transition from IV to oral therapy or even facilitating initial outpatient treatment for appropriate patients. This could lead to substantial benefits, including reduced healthcare costs, decreased hospital stays, and improved patient convenience. The drug's demonstrated non-inferiority to intravenous ertapenem in clinical trials underscores its efficacy against these challenging pathogens. However, this advancement also brings critical considerations. The broader availability of an oral carbapenem, while beneficial, necessitates vigilant antimicrobial stewardship to mitigate the risk of accelerating carbapenem resistance, a concern highlighted by existing literature on carbapenem overuse. Furthermore, while tebipenem shows strong activity against common uropathogens like E. coli and K. pneumoniae, its efficacy against other species such as Proteus mirabilis or Enterococcus faecium may vary, underscoring the continued importance of precise pathogen identification and susceptibility testing. Clinicians will also need to consider patient-specific factors, such as renal function and seizure history, due to known carbapenem-class effects. Ultimately, Utebzi's approval provides a powerful new tool, but its optimal integration into clinical practice will depend on judicious use and ongoing surveillance of resistance patterns.